Shahnaz Shahinfar
Overview
Explore the profile of Shahnaz Shahinfar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
2187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Holtkamp F, de Zeeuw D, Thomas M, Cooper M, de Graeff P, Hillege H, et al.
Kidney Int
. 2011 Apr;
80(3):282-7.
PMID: 21451458
Intervention in the renin-angiotensin-aldosterone-system (RAAS) is associated with slowing the progressive loss of renal function. During initiation of therapy, however, there may be an acute fall in glomerular filtration rate...
12.
Webb N, Lam C, Shahinfar S, Strehlau J, Wells T, Gleim G, et al.
Nephrol Dial Transplant
. 2011 Feb;
26(8):2521-6.
PMID: 21285125
Background: No prospective, randomized, double-blind trials of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers have previously been reported in adults or children with proteinuria secondary to Alport syndrome. Methods: This...
13.
Lambers Heerspink H, Gansevoort R, Brenner B, Cooper M, Parving H, Shahinfar S, et al.
J Am Soc Nephrol
. 2010 Jul;
21(8):1355-60.
PMID: 20634296
There are many methods to screen for abnormal amounts of proteinuria to identify patients at risk for progression of renal disease, but which method best predicts renal risk is unknown....
14.
Webb N, Lam C, Loeys T, Shahinfar S, Strehlau J, Wells T, et al.
Clin J Am Soc Nephrol
. 2010 Jan;
5(3):417-24.
PMID: 20089489
Background And Objectives: No large, randomized, double-blind trials in children with proteinuria treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers have previously been reported. Design, Setting, Participants, & Measurements:...
15.
Parving H, de Zeeuw D, Cooper M, Remuzzi G, Liu N, Lunceford J, et al.
J Am Soc Nephrol
. 2008 Jan;
19(4):771-9.
PMID: 18199798
Losartan treatment reduced renal outcomes in proteinuric patients with type 2 diabetes in the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study. It is unknown...
16.
Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study
Tershakovec A, Keane W, Zhang Z, Lyle P, Appel G, McGill J, et al.
Diabetes Care
. 2007 Dec;
31(3):445-7.
PMID: 18070995
Renal pathology and dyslipidemia commonly coexist. Treatments that lower albuminuria/proteinuria may lower lipids, but it is not known whether lipid lowering independent of lessening albuminuria/proteinuria slows progression of kidney disease....
17.
Keane W, Zhang Z, Lyle P, Cooper M, de Zeeuw D, Grunfeld J, et al.
Clin J Am Soc Nephrol
. 2007 Aug;
1(4):761-7.
PMID: 17699284
Diabetic nephropathy is the most important cause of ESRD. The aim of this study was to develop a risk score from risk predictors for ESRD, with and without death, in...
18.
Eijkelkamp W, Zhang Z, Remuzzi G, Parving H, Cooper M, Keane W, et al.
J Am Soc Nephrol
. 2007 Apr;
18(5):1540-6.
PMID: 17409317
Albuminuria reduction could be renoprotective in hypertensive patients with diabetic nephropathy. However, the current use of renin-angiotensin-system intervention is targeted to BP only. Therefore, this study investigated the adequacy of...
19.
Eijkelkamp W, Zhang Z, Brenner B, Cooper M, Devereux R, Dahlof B, et al.
J Hypertens
. 2007 Mar;
25(4):871-6.
PMID: 17351381
Objective: To investigate whether a threshold exists for cardiovascular risk in type 2 diabetic patients with hypertension, the association between renal function and cardiovascular risk was examined across the entire...
20.
Hogg R, Delucchi A, Sakihara G, Wells T, Tenney F, Batisky D, et al.
Pediatr Nephrol
. 2007 Jan;
22(5):695-701.
PMID: 17216247
The pharmacokinetic (PK) parameters of lisinopril were obtained in 46 children aged 6 months to 15 years. A lisinopril suspension (0.15 mg/kg per day) was administered to patients <6 years...